Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (DE:MOL)
:MOL
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.51Last Year’s EPS
-1.86Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 24, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Moleculin Biotech, emphasizing the promising data from the Phase 2 trial of Annamycin and the initiation of the MIRACLE Phase 3 trial. The company's solid financial position and clear focus on future milestones are also highlighted. However, there are challenges related to delayed enrollment in the US and the high cost of the Phase 3 trial.Company Guidance
During the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call, the company provided detailed guidance on the progress of their MIRACLE Phase 3 pivotal trial for Annamycin in combination with Cytarabine for relapsed and refractory AML patients. The trial is set across 25 sites in the US, Europe, and the Middle East, with patient screening underway and treatment expected to begin soon. The trial includes two parts, with multiple unblindings of data planned to enhance visibility for stakeholders. The first unblinding will occur after 45 subjects, expected by the end of 2025, and a second between 75 and 90 subjects in the first half of 2026. Annamycin's previous Phase 2 data showed promising results with an 11-month overall survival and a 50% complete remission rate, surpassing existing therapies. Moleculin also highlighted financial metrics, reporting cash on hand and recent capital raises totaling approximately $13 million, which will support operations into Q3 2025. The company aims to keep its cash burn at $5 million per quarter, increasing to $7-8 million as they progress into 2026.Launch of MIRACLE Phase 3 Trial
Moleculin Biotech has launched the MIRACLE Phase 3 pivotal trial for Annamycin in combination with Cytarabine for the second line treatment of relapsed and refractory AML patients. Regulatory and ethics approval has been obtained in the first European country, and patient screening has begun.
Positive Phase 2 Data for Annamycin
Phase 2 data shows Annamycin achieving a 50% complete remission rate in second-line AML patients, with a median progression-free survival of nine months and overall survival at 11 months. The drug has shown better performance than any existing therapies with a comparable CR rate.
Strong Financial Position
Moleculin Biotech has raised approximately $9 million in February 2025, leading to a combined cash balance of $13 million, extending runway into the third quarter of 2025.
Potential Game-Changer for AML Treatment
Annamycin has shown no drug-related cardiotoxicity and overcomes resistance to Venetoclax in AML. It is recognized as potentially the first non-cardiotoxic anthracycline, with experts acknowledging its significance.
Pipeline and Future Milestones
Moleculin is planning to publicly release data from MB107 in April and hopes to develop a pivotal investigator-initiated trial in Europe later in 2025. The company is focused on operational execution and meeting its milestones.
---
DE:MOL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:MOL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 24, 2025 | €6.45 | €6.45 | 0.00% |
| Nov 11, 2024 | €6.45 | €6.45 | 0.00% |
| Aug 14, 2024 | €6.45 | €6.45 | 0.00% |
| May 13, 2024 | €6.45 | €6.45 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Moleculin Biotech (DE:MOL) report earnings?
Moleculin Biotech (DE:MOL) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Moleculin Biotech (DE:MOL) earnings time?
Moleculin Biotech (DE:MOL) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Moleculin Biotech stock?
The P/E ratio of Moleculin Biotech is N/A.
What is DE:MOL EPS forecast?
DE:MOL EPS forecast for the fiscal quarter 2025 (Q1) is -0.51.
---